Search

everythinglearnresearchcommunity

for

Search:↓

Blocking cholesterol production may help control hair loss in Primary Cicatricial Alopecia by affecting key regulators.

A woman experienced sudden hair graying and loss after a COVID-19 vaccine, which improved with treatment.

COVID-19 affects multiple body systems and complicates treatment; accurate testing is crucial.

Pregnancy and nursing increase certain brain activities in rats, but these changes disappear when the babies are taken away.

Some medications can help increase sexual desire and function in women.

Women with schizophrenia on atypical antipsychotics are more likely to have polycystic ovarian syndrome (PCOS) than women without schizophrenia.

Mouse Scube3 affects teeth, tongue, vibrissae, and eye development, but not facial structure or limb growth.

Deuruxolitinib significantly helps regrow scalp hair in adults with moderate to severe alopecia areata.

Hair transplant surgery may cause alopecia areata, a new possible complication.

Certain genetic factors may contribute to frontal fibrosing alopecia in Brazil.

Some patients on Baricitinib for alopecia areata lost response, often linked to longer and more severe initial conditions.

Nanoparticles with more oleic acid improved the delivery and stability of the drug spironolactone.

Finasteride effectively reduces symptoms of enlarged prostate with minimal side effects.

Chitosan-coated spironolactone nano carriers effectively treat acne without side effects.

Both photobiomodulation and low-frequency treatments effectively reduce body measurements.

The nutraceutical with rosemary may reduce inflammation in dog skin.

Healthy lifestyle changes, especially weight loss, can improve symptoms and overall health in people with Polycystic Ovary Syndrome, especially if they are overweight or obese.

Caffeine intake during pregnancy and lactation can cause skin lesions in mother rats and their babies, not linked to cortisol levels.

Baricitinib treatment for severe alopecia areata shows significant improvement by 52 weeks, especially in very severe cases.

Baricitinib therapy helped many patients with severe alopecia regrow hair after 52 weeks.

Alopecia areata is likely an autoimmune disease with unclear triggers, involving various immune cells and molecules, and currently has no cure.

Deuruxolitinib effectively promotes hair regrowth in adults with alopecia areata.

Stress may trigger hair loss by affecting immune protection in hair follicles.

Early and personalized treatment for hair loss in young people is crucial to prevent permanent damage and should include psychological support.

Alopecia is linked to various health and mental conditions, impacts life quality, and needs medical attention beyond its cosmetic effects.

Avoiding certain allergens in personal care products may improve symptoms for some patients with lichen planopilaris or frontal fibrosing alopecia.

Most people with Alopecia Areata don't get treatment within a year; it's costly and often comes with other health issues.

Alopecia areata severity is influenced by factors like long disease duration, relapses, treatment response, and mental health, leading to the creation of a new severity measurement tool.

Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.